Drug Trial Radar · NCT00970931
Hypertension Prevention in Pre-Hypertensive Individuals
Last checked: Nov 20, 2026Latest source record: Feb 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
730
Actual
Start
Jul 2010
Primary completion
Sep 2014
Study completion Sep 2014
Sponsor
- Lead sponsor
- Hospital de Clinicas de Porto AlegreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Financiadora de Estudos e Projetos
- First posted
- Sep 3, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 30 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The incidence of hypertension in individuals with pre-hypertension was 80% in ten years in a study conducted in Southern Brazil. The effectiveness of non-drug interventions to prevent hypertension is low in the long term. It may be hypothesized that a population-based drug intervention could reduce relevantly the burden of hypertension and cardiovascular disease. Diuretics are at least as efficacious as other blood pressure-lowering drugs, are well tolerated, have longer duration of action and the advantage of very low cost to be used in a population intervention. Chlorthalidone is the more efficacious agent. Its main limitation is to induce hypokalemia in a proportion of patients, an adverse effect that can be antagonized by a potassium-sparing diuretic, as amiloride. A study with this objective is therefore recommendable in Brazil, in order to support a plan of precocious intervention in individuals with pre-hypertension. Such a study was demanded and funded by the Health and Technology Ministries in Brazil.
Conditions
- Pre-hypertension
- Hypertension
- Cardiovascular Disease
Interventions
Chlorthalidone plus amilorideDrug
Oral Chlorthalidone 12.5 mg plus amiloride 2.5 mg, once a day for 18 months
placeboDrug
Oral placebo once a day, for 18 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of hypertension, by blood pressure ≥ 140/90 mmHg in individuals without diabetes or ≥ 135/85 mmHg in participants with diabetes.Time frame: 18 months
- Adverse events.Time frame: 18 months
- Development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKGTime frame: 18 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hospital de Clínicas de Porto Alegre, UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.